InflaRx N.V.

NasdaqGS:IFRX Voorraadrapport

Marktkapitalisatie: US$403.6m

InflaRx Beheer

Beheer criteriumcontroles 2/4

De CEO InflaRx is Niels Riedemann, benoemd in Jan2007, heeft een ambtstermijn van 19.33 jaar. bezit rechtstreeks 0.73% van de aandelen van het bedrijf, ter waarde $ 2.93M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 7 jaar.

Belangrijke informatie

Niels Riedemann

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO19.3yrs
Eigendom CEO0.7%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur7yrs

Recente managementupdates

Recent updates

Analyseartikel • Feb 06

Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Nov 20

InflaRx: Gohibic Remains Niche, INF904 Underwhelms, Cash Burn Accelerates (Rating Downgrade)

Summary InflaRx faces worsening prospects as Gohibic remains niche, unprofitable, and unlikely to drive meaningful revenue growth. Attempts to expand vilobelimab into new indications failed, prompting a strategic pivot to the early-stage asset INF904. Early INF904 data in HS and CSU are underwhelming, with class safety concerns and past failures weighing on IFRX's outlook. With dwindling cash reserves and a high burn rate, IFRX is rated a clear 'Sell' due to excessive risks and uncertain turnaround. Read the full article on Seeking Alpha
Analyseartikel • Jul 10

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Jun 25

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Dec 23

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Aug 17

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Mar 28

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Nov 30

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 29

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

German clinical-stage biopharma InflaRx (NASDAQ:IFRX) on Thursday said it had submitted an emergency use approval request to the U.S. FDA for its monoclonal antibody vilobelimab to treat critically ill COVID-19 patients. The company also said it was granted a fast track designation from the U.S. drug regulator for vilobelimab. IFRX stock +5.6% to $2.63 in early trading. The submission for the emergency use nod and the fast track clearance was based on the results of phase 3 studies conducted in invasively mechanically ventilated, critically ill COVID patients, IFRX said in a statement. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The submission from InflaRx (IFRX) comes at a time when COVID cases in the U.S. are expected to rise in the fall and winter season.
Seeking Alpha • Aug 05

InflaRx reports Q2 results

InflaRx press release (NASDAQ:IFRX): Q2 GAAP EPS of €0.01. On June 30, 2022, the Company’s total funds available were approximately €91.8 million, composed of cash and cash equivalents of €15.4 million and marketable securities of €76.4 million. These funds are expected to finance operations until year-end 2024.
Seeking Alpha • Jul 26

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

InflaRx (NASDAQ:IFRX) stock rose ~13% on July 26 after its CEO Niels Riedemann said the company plans to submit a request for an emergency use authorization (EUA) of its COVID-19 drug vilobelimab in the U.S. by the end of Q3. The Germany company said it had encouraging interactions with the U.S. Food and Drug Administration (FDA) at a recent Type B meeting which was held to discuss a potential EUA filing and the development of monoclonal antibody vilobelimab for critically ill invasively mechanically ventilated patients with COVID-19. InflaRx noted that it discussed in detail a completed phase 3 part of the PANAMO study in invasively mechanically ventilated, critically ill patients with COVID-19. In March, the company reported data from the phase 3 trial in which vilobelimab did not show statistical significance in reducing risk of death in mechanically ventilated patients with COVID-19. "Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients," said InflaRx Founder and CEO Riedemann.
Analyseartikel • Jul 16

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jul 06

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release. Vilobelimab has already received orphan drug status for PG in the U.S. and EU. IFRX +14.08% to $1.62 premarket July 6
Seeking Alpha • Jun 29

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

German biotech InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday that the FDA agreed to a Type B meeting as the company seeks emergency use authorization for its COVID-19 therapy, vilobelimab  InflaRx (IFRX) has engaged the agency to discuss the future regulatory path for vilobelimab in COVID-19 after its multi-national PANAMO study for patients with the severe form of the disease generated favorable Phase 3 results early this year. The FDA has scheduled a Type B meeting for early Q3 to provide guidance on a potential emergency use authorization submission. Meanwhile, the discussions with the European Medicines Agency (EMA) are currently underway, targeting a regulatory submission for the same indication. Updating on the development of vilobelimab for the rare skin disorder pyoderma gangrenosum, InflaRx (IFRX) said that the company is now finalizing the design for a Phase III trial. That was after an end-of-phase II meeting, in which the FDA supported a randomized, controlled late-stage study and offered to review the study protocol. Read more on the topline data from the PANAMO study.
Analyseartikel • Apr 01

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Dec 29

Our First Look At InflaRx

Today, we shine the spotlight on InflaRx, a small biotech concern based in Germany. The stock is deep in 'Busted IPO' territory even as the company has seen an increasing amount of news flow around it in recent months. A full investment analysis follows in the paragraphs below.

CEO

Niels Riedemann (52 yo)

19.3yrs
Tenure

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. He founded InflaRx N.V. in 2007 as InflaRx GmbH. He spent several years in bas...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Niels Riedemann
Co-Founder19.3yrsgeen gegevens0.73%
$ 2.9m
Renfeng Guo
Co-Founder19.3yrsgeen gegevens1.2%
$ 4.8m
Thomas Taapken
Chief Financial Officer5.6yrsgeen gegevens0.0024%
$ 9.6k
Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance3.1yrsgeen gegevens0%
$ 0
Camilla Chong
Chief Medical Officer2.8yrsgeen gegevens0%
$ 0
Jan Medina
Head of Investor Relations & VP2.3yrsgeen gegevensgeen gegevens
Christian Schmid
VP and Head of Legal Affairs & General Counselno datageen gegevensgeen gegevens
Maria Habel
VP, Head of Preclinical R&D and QC13.3yrsgeen gegevensgeen gegevens
Kofi Boaten
VP and Head of Supply Quality & Clinical Trial Suppliesno datageen gegevensgeen gegevens
Peter Hurt
Senior Director and Head of Drug Safety & Pharmacovigilianceno datageen gegevensgeen gegevens
Daniel Vetter
Senior Director & Head of IT3.8yrsgeen gegevensgeen gegevens
Igor Orshanskiy
Senior Director & Head of Business Development2.5yrsgeen gegevensgeen gegevens
3.8yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van IFRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Niels Riedemann
Co-Founderno datageen gegevens0.73%
$ 2.9m
Renfeng Guo
Co-Founderno datageen gegevens1.2%
$ 4.8m
Nicolas Fulpius
Independent Chairman of the Board19.3yrsgeen gegevens0.33%
$ 1.3m
K. Reinhart
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
P. Ward
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Richard Brudnick
Independent Non-Executive Director7yrsgeen gegevens0.034%
$ 137.0k
Hege Hellstrom
Non-Executive Director3.1yrsgeen gegevens0%
$ 0
Mark Kubler
Independent Non-Executive Director11.3yrsgeen gegevens0.65%
$ 2.6m
Anthony Gibney
Independent Non-Executive Director5yrsgeen gegevens0.0068%
$ 27.4k
7.0yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IFRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/27 23:35
Aandelenkoers aan het einde van de dag2026/05/27 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

InflaRx N.V. wordt gevolgd door 16 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Madhu KumarBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.